Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®)

Haemophilia

Volumn 17, Issue 3, 2011, Pages 407-411

  Bacon, C L ^a   Singleton, E ^a   Brady, B ^b   White, B ^b   Nolan, B ^a   Gilmore, R M ^a   Ryan, C ^c   Keohane, C ^a   Vince Jenkins, P ^a   O'Donnell, J S ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^c University College Cork and INFANT Centre   (Ireland)

Author keywords

Factor VIII inhibitor; Haemophilia; Recombinant factor VIII; Surveillance

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADULT; ANIMAL CELL; ARTICLE; CHO CELL; DISEASE SEVERITY; DRUG EXPOSURE; HEMOPHILIA A; HUMAN; IRELAND; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AUTOANTIBODIES; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHILD, PRESCHOOL; FACTOR VIII; HEMOPHILIA A; HUMANS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SERUM ALBUMIN; YOUNG ADULT;

EID: 79955163296     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02430.x     Document Type: Article

References (33)

1. Astermark J, Lacroix-Desmazes S, Reding MT. Inhibitor development. Haemophilia 2008; 14(Suppl. 3): 36-42.
2. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
3. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453-9.
4. McMillan CW, Shapiro SS, Whitehurst D et al. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71: 344-8.
5. Sultan Y. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group. Thromb Haemost 1992; 67: 600-2.
6. Colvin BT, Hay CR, Hill FG, Preston FE. The incidence of factor VIII inhibitors in the United Kingdom, 1990-93. Inhibitor Working Party. United Kingdom Haemophilia Centre Directors Organization. Br J Haematol 1995; 89: 908-10.
7. Goudemand J. Pharmaco-economic aspects of inhibitor treatment. Eur J Haematol Suppl 1998; 63: 24-7.
8. Rosendaal FR, Varekamp I, Smit C et al. Mortality and causes of death in Dutch haemophiliacs, 1973-86. Br J Haematol 1989; 71: 71-6.
9. Astermark J. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia 2006; 12(Suppl. 3): 52-60.
10. Hay CR. The epidemiology of factor VIII inhibitors. Haemophilia 2006; 12(Suppl. 6): 23-8.
11. Oldenburg J, Schroder J, Brackmann HH et al. Environmental and genetic factors influencing inhibitor development. Semin Hematol 2004; 41: 82-8.
12. Astermark J, Berntorp E, White GC, Kroner BL. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267-72.
13. Shapiro SS. Genetic predisposition to inhibitor formation. Prog Clin Biol Res 1984; 150: 45-55.
14. Aledort LM, Dimichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 1998; 4: 68.
15. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-72.
16. Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001; 113: 600-3.
17. van der Bom JG, Mauser-Bunschoten EP, Fischer K, van den Berg HM. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost 2003; 89: 475-9.
18. von Auer CH, Oldenburg J, von Depka M et al. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates. Ann N Y Acad Sci 2005; 1051: 498-505.
19. Sharathkumar A, Lillicrap D, Blanchette VS et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1: 1228-36.
20. Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69: 115-8.
21. Rosendaal FR, Nieuwenhuis HK, van den Berg HM et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. Blood 1993; 81: 2180-6.
22. Blanchette VS, Shapiro AD, Liesner RJ et al. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6: 1319-26.
23. Tarantino MD, Collins PW, Hay CR et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004; 10: 428-37.
24. Verbruggen B, Novakova I, Wessels H et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
25. Singleton E, Smith J, Kavanagh M, Nolan B, White B. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII. Thromb Haemost 2007; 98: 1188-92.
26. Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 2004; 22: 1393-8.
27. Grillberger L, Kreil TR, Nasr S, Reiter M. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J 2009; 4: 186-201.
28. Ironside JW, Head MW. Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products. Haemophilia 2004; 10(Suppl. 4): 64-9.
29. Llewelyn CA, Hewitt PE, Knight RS et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363: 417-21.
30. Ludlam CA, Turner ML. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products. Br J Haematol 2006; 132: 13-24.
31. Mauser-Bunschoten EP, Rosendaal FR, Nieuwenhuis HK et al. Clinical course of factor VIII inhibitors developed after exposure to a pasteurised Dutch concentrate compared to classic inhibitors in hemophilia A. Thromb Haemost 1994; 71: 703-6.
32. Sawamoto Y, Prescott R, Zhong D et al. Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors. Thromb Haemost 1998; 79: 62-8.
33. Astermark J. Overview of inhibitors. Semin Hematol 2006; 43: S3-7.